| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $204,496,807 ) (Continued on the next page) |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01EB033651 | Nanosensor Array Platform to Capture Whole Disease Fingerprints | 000 | 2 | NIH | 5/20/2024 | $640,165 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA243904 | Ontogeny and Function of Tumor-Resident Innate Lymphocytes and Innate-Like T Cells | 000 | 5 | NIH | 5/22/2024 | $485,492 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA193842 | Characterizing the MSI2 network in leukemia | 000 | 9 | NIH | 11/15/2023 | $371,921 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | T32CA254875 | Molecular Imaging in Cancer Biology Training Program | 000 | 4 | NIH | 8/1/2024 | $401,161 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA244866 | Exercise as Interception Therapy in Primary High Risk Cancer | 000 | 5 | NIH | 5/27/2024 | $624,661 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35NS105109 | Molecular Mechanisms of Drug Resistance in Primary Brain Tumors | 000 | 7 | NIH | 11/27/2023 | $540,855 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA253913 | Comparative Modeling of Effective Policies for Colorectal Cancer Control | 001 | 5 | NIH | 9/2/2024 | $1,279,175 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37AI093808 | INITIATION OF THE IMMUNE RESPONSE TO ASPERGILLUS FUMIGATUS | 000 | 15 | NIH | 6/26/2024 | $670,541 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA261183 | Immune control and genomic instability at micronuclei | 000 | 3 | NIH | 12/6/2023 | $424,822 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA245069 | Defining the impact of mutant oncogene zygosity | 000 | 5 | NIH | 2/28/2024 | $364,399 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35NS105109 | Molecular Mechanisms of Drug Resistance in Primary Brain Tumors | 002 | 7 | NIH | 5/14/2024 | -$18,028 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AG074004 | Impact of sex differences on the trajectory of interactome dysfunctions across the AD spectrum | 000 | 4 | NIH | 5/16/2024 | $1,182,309 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35NS105109 | Molecular Mechanisms of Drug Resistance in Primary Brain Tumors | 001 | 7 | NIH | 4/10/2024 | $60,095 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA261183 | Immune control and genomic instability at micronuclei | 001 | 3 | NIH | 4/17/2024 | $23,600 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA245069 | Defining the impact of mutant oncogene zygosity | 001 | 5 | NIH | 4/17/2024 | $20,245 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA248665 | A Randomized Trial to Minimize Non-Response to Aerobic Training in Operable Breast Cancer | 000 | 5 | NIH | 2/27/2024 | $587,721 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA248665 | A Randomized Trial to Minimize Non-Response to Aerobic Training in Operable Breast Cancer | 001 | 5 | NIH | 4/17/2024 | $32,650 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA277833 | Reducing the chasm in behavioral health care for older adults with cancer: Development of the Center for Implementation Research in Cancer in Later Life (CIRCL) | 001 | 2 | NIH | 8/24/2024 | $205,818 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | P50CA247749 | MSK SPORE in Genomic Instability in Breast Cancer | 001 | 5 | NIH | 7/23/2024 | $2,348,168 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI100874 | The natural killer cell response against mouse cytomegalovirus infection | 000 | 12 | NIH | 11/17/2023 | $567,260 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI100874 | The natural killer cell response against mouse cytomegalovirus infection | 001 | 12 | NIH | 5/16/2024 | $63,030 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012203 | New approaches for leveraging single-cell data to identify disease-critical genes and gene sets | 001 | 4 | NIH | 3/13/2024 | $224,101 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R03CA286680 | PSMA ligand radiosensitizers to improve the therapeutic index of external beam radiotherapy for prostate cancer | 000 | 1 | NIH | 3/18/2024 | $88,000 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01GM144508 | Mechanisms of enhancer-promoter communication, genome organization and transcription control | 000 | 3 | NIH | 4/4/2024 | $435,861 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA285746 | Enhanced Pain Coping in Cancer (EPIC) | 000 | 1 | NIH | 7/1/2024 | $732,536 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01GM144508 | Mechanisms of enhancer-promoter communication, genome organization and transcription control | 001 | 3 | NIH | 6/21/2024 | $48,429 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012203 | New approaches for leveraging single-cell data to identify disease-critical genes and gene sets | 002 | 4 | NIH | 8/7/2024 | $19,919 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012203 | New approaches for leveraging single-cell data to identify disease-critical genes and gene sets | 003 | 4 | NIH | 9/4/2024 | $4,980 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | P01CA228696 | The Impact of DNA Damage Repair Abnormalities in Prostate Cancer | 001 | 5 | NIH | 9/13/2024 | $1,617,094 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258886 | Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma | 001 | 4 | NIH | 4/22/2024 | $24,316 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01DK124913 | Lipid Droplets and Transcriptional Regulation of Metabolism | 001 | 5 | NIH | 5/21/2024 | $30,865 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258886 | Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma | 000 | 4 | NIH | 3/6/2024 | $437,680 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01HD094868 | Decoding cell states and tissue morphogenesis in the early mammalian embryo | 000 | 6 | NIH | 6/21/2024 | $586,084 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | P01CA275746 | Leveraging Observational (Real World) Data to Advance Precision Oncology | 000 | 1 | NIH | 9/3/2024 | $2,372,456 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | T32CA275764 | Oncology-focused Postdoctoral Training in Care Delivery and Symptom Science (OPTICS) | 001 | 2 | NIH | 7/1/2024 | $557,680 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA270018 | Deciphering the Acidic Tumor Environment: A Phase I/IIa Study of Pre-Operative Multiparametric MRI and pHLIP® ICG Intra-Operative Fluorescence Imaging of Primary Breast Cancer | 001 | 2 | NIH | 4/17/2024 | $33,819 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA193837 | Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence | 001 | 9 | NIH | 4/18/2024 | $23,578 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01DK101989 | Uncovering the role for MSI2 network in hematopoietic stem cells | 000 | 10 | NIH | 6/26/2024 | $607,423 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R50CA243895 | Organic Synthesis at the Service of Biology and Medicine | 000 | 6 | NIH | 7/22/2024 | $247,416 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01DK124913 | Lipid Droplets and Transcriptional Regulation of Metabolism | 000 | 5 | NIH | 2/21/2024 | $463,008 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01FD008299 | Integrative proteogenomics for elucidation of tumor-specific cell surface proteomes in ultra-rare cancers | 001 | 1 | FDA | 9/19/2024 | $0 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01GM129058 | Replication Of Chromosomes In Budding Yeast | 002 | 5 | NIH | 1/12/2024 | -$2,600 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01GM129058 | Replication Of Chromosomes In Budding Yeast | 001 | 5 | NIH | 12/27/2023 | $460,223 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA285621 | Meaning-Centered Psychotherapy to Meet Palliative Care Needs of Cancer Caregivers | 001 | 1 | NIH | 1/12/2024 | -$1,871 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21EB033985 | Rapid Free-Breathing 3D High-Resolution MRI for Volumetric Liver Iron Quantification | 000 | 2 | NIH | 7/19/2024 | $265,500 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA288502 | Social Genomic Mechanisms Linking Structural Racism, Perceived Discrimination, and Breast Cancer Survival | 000 | 1 | NIH | 8/23/2024 | $582,548 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA245206 | Exploring the combinatorial efficacy between chemotherapy and T cell checkpoint inhibition and the role of cellular senescence | 000 | 5 | NIH | 6/26/2024 | $260,099 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA285621 | Meaning-Centered Psychotherapy to Meet Palliative Care Needs of Cancer Caregivers | 000 | 1 | NIH | 1/1/2024 | $444,572 |
| | 2024 | 2024 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVENUE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01HD108914 | Essential roles for RNAi/hpRNAs to resolve intragenomic conflicts in the male germline | 000 | 3 | NIH | 5/6/2024 | $574,137 |
|
